ZA968783B - Flupirtine usage - Google Patents

Flupirtine usage

Info

Publication number
ZA968783B
ZA968783B ZA968783A ZA968783A ZA968783B ZA 968783 B ZA968783 B ZA 968783B ZA 968783 A ZA968783 A ZA 968783A ZA 968783 A ZA968783 A ZA 968783A ZA 968783 B ZA968783 B ZA 968783B
Authority
ZA
South Africa
Prior art keywords
flupirtine
usage
patients
prophylaxis
impairment
Prior art date
Application number
ZA968783A
Other languages
English (en)
Inventor
Gabriela Dr Pergande
Werner E G Prof Mueller
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of ZA968783B publication Critical patent/ZA968783B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA968783A 1995-11-07 1996-10-18 Flupirtine usage ZA968783B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19541405A DE19541405A1 (de) 1995-11-07 1995-11-07 Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen

Publications (1)

Publication Number Publication Date
ZA968783B true ZA968783B (en) 1997-05-27

Family

ID=7776799

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA968783A ZA968783B (en) 1995-11-07 1996-10-18 Flupirtine usage

Country Status (27)

Country Link
US (2) US6034111A (fr)
EP (1) EP0859613B1 (fr)
JP (1) JPH11514652A (fr)
KR (1) KR100512673B1 (fr)
CN (1) CN1116037C (fr)
AT (1) ATE316789T1 (fr)
AU (1) AU711207B2 (fr)
BG (1) BG63149B1 (fr)
BR (1) BR9611588A (fr)
CA (1) CA2189705C (fr)
CZ (1) CZ298115B6 (fr)
DE (2) DE19541405A1 (fr)
DK (1) DK0859613T3 (fr)
ES (1) ES2257755T3 (fr)
HK (1) HK1016508A1 (fr)
HU (1) HU225742B1 (fr)
MX (1) MX9803610A (fr)
NO (1) NO315074B1 (fr)
NZ (1) NZ330414A (fr)
PL (1) PL186537B1 (fr)
PT (1) PT859613E (fr)
RU (1) RU2200555C2 (fr)
SK (1) SK284601B6 (fr)
TW (1) TW393317B (fr)
UA (1) UA51682C2 (fr)
WO (1) WO1997017072A2 (fr)
ZA (1) ZA968783B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
EP1688141A1 (fr) * 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102009023162B4 (de) * 2009-05-29 2011-07-07 Corden PharmaChem GmbH, 68305 Verfahren zur Herstellung von Flupirtin
US9212416B2 (en) * 2009-08-07 2015-12-15 Swagelok Company Low temperature carburization under soft vacuum
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
WO2013127539A2 (fr) * 2012-03-02 2013-09-06 Meda Pharma Gmbh & Co. Kg Formulations pharmaceutiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN172468B (fr) * 1990-07-14 1993-08-14 Asta Medica Ag
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin

Also Published As

Publication number Publication date
BR9611588A (pt) 1999-04-06
EP0859613B1 (fr) 2006-02-01
UA51682C2 (uk) 2002-12-16
US6034111A (en) 2000-03-07
KR100512673B1 (ko) 2005-12-09
NO981898D0 (no) 1998-04-27
WO1997017072A2 (fr) 1997-05-15
HU225742B1 (en) 2007-07-30
CA2189705A1 (fr) 1997-05-08
US6034112A (en) 2000-03-07
PL186537B1 (pl) 2004-01-30
CZ298115B6 (cs) 2007-06-27
SK58698A3 (en) 1998-09-09
HUP9901659A2 (hu) 1999-09-28
WO1997017072A3 (fr) 1997-07-24
ATE316789T1 (de) 2006-02-15
CN1116037C (zh) 2003-07-30
CZ128398A3 (cs) 1998-09-16
SK284601B6 (sk) 2005-07-01
AU711207B2 (en) 1999-10-07
TW393317B (en) 2000-06-11
DE59611327D1 (de) 2006-04-13
HK1016508A1 (en) 1999-11-05
NO981898L (no) 1998-04-27
CN1201391A (zh) 1998-12-09
NZ330414A (en) 1999-10-28
HUP9901659A3 (en) 2001-04-28
DE19541405A1 (de) 1997-05-15
JPH11514652A (ja) 1999-12-14
EP0859613A2 (fr) 1998-08-26
PT859613E (pt) 2006-06-30
BG102404A (en) 1998-12-30
ES2257755T3 (es) 2006-08-01
RU2200555C2 (ru) 2003-03-20
NO315074B1 (no) 2003-07-07
BG63149B1 (bg) 2001-05-31
PL326629A1 (en) 1998-10-12
CA2189705C (fr) 2005-08-09
AU1716597A (en) 1997-05-29
DK0859613T3 (da) 2006-06-06
MX9803610A (es) 1998-09-30
KR19990067366A (ko) 1999-08-16

Similar Documents

Publication Publication Date Title
AU586860B2 (en) Therapeutical application of phosphonylmethoxyalkyl adenines
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
TW371660B (en) Therapeutic nucleosides a purine carbocyclic nucleosides for treatment of HIV and HBV infections
YU18899A (sh) L-nukleozidi purina, njihovi analogoni i primena
MY117892A (en) Therapeutic compounds
FI956014A (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
IE900073L (en) Treatment of diseases associated with hiv infections
ZA968783B (en) Flupirtine usage
AP9801286A0 (en) Therapeutic compounds.
IE892654L (en) Therapeutic nucleosides
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
NZ512850A (en) Treatment of papillomavirus infections
AU4111600A (en) The use of gssg reductase for the therapy and prophylaxis of hiv infected patients
FR2632525B1 (fr) Application therapeutique de la myeloperoxydase humaine
AU5535498A (en) Treatment of HIV positive patients
WO1997026880A3 (fr) Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1
MX9700560A (es) Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.
AU2396900A (en) Treatment and prevention of hiv and other viral infections
AU2211592A (en) Method of treatment for latent virus infection
MD1051C2 (ro) Remediu antiherpetic
ES8700940A1 (es) Procedimiento de obtencion de composiciones para el trata- miento de infecciones por rinovirus
AU2450900A (en) Therapeutic nucleoside compound
WO1988008707A3 (fr) Derives de rubradirine pour le traitement de l'infection hiv
GR950100315A (el) Φαρμακευτικο παρασκευασμα βασιζομενο σε εναιωρημα εμβρυικων κυτταρων με ανοσοδιορθωτικη δραση και μεθοδος θεραπειας ζαχαρωδους διαβητη με τη χρηση αυτου του παρασκευασματος.
AU5657590A (en) Beta-hydroxamate d-aspartic acid for treatment of viral infections and tumours